Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹50.10 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹50.10 Cr |
| Fresh Issue | ₹47.58 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹71.00-73.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543828 |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Gretex Corporate Services Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,600 shares and in multiples thereof
Incorporated in 2008, Mumbai based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility to source and supply generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API (Active Pharmaceutical Ingredients), and Intermediates. Based on clients' specifications and requirements, they outsource the manufacturing facility from the suppliers in India and abroad.
The generic products supplied by the company have a wide application in paint, food, pharma, and adhesive industry. The company is involved in a contract manufacturing facility, supply and outsource of medicines and pharma formulation to hospitals, NGO, government and healthcare institutes. SPIL has 50 pharma formulations which are supplied under the brand name in the form of tablets, ointment, capsules, and injectable.
The company has its own sales force and distribution network in 5 states for ethical marketing of pharmaceutical formulation & products under the brand name in Indian and international markets. It also offers formulation development and QC services and provides customised solutions.
The competitive strengths of the company are:
1. Customer-centric and order-driven business model
2. Wide range of product offerings
3. Contract manufacturing facility arrangements
4. Strong distribution, marketing, and sales network
5. Diversified business operations
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To set up a dedicated manufacturing facility for Pharmaceutical Business | 12.50 |
| 2 | Distribution and Warehousing Centre‘s & Purchase of Corporate Office | 4.50 |
| 3 | Additional Working Capital | 5.25 |
| 4 | General Corporate Expenses | 2.80 |
| Period Ended | 30 Sep 2022 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 164.02 | 137.52 | 99.26 |
| Total Income | 195.90 | 357.56 | 193.73 |
| Profit After Tax | 3.61 | 5.30 | 2.67 |
| NET Worth | 51.09 | 29.78 | 22.51 |
| Reserves and Surplus | 39.97 | 20.03 | 12.96 |
| Total Borrowing | 49.41 | 30.59 | 29.77 |
| Amount in ₹ Crore | |||
| KPI | |
|---|---|
| ROE | 17.81% |
| ROCE | 38.59% |
| Debt / Equity | 1.09% |
| RoNW | 17.81% |
| PAT Margin | 1.49% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 5.52 | |
| P/E (x) | 24.33 | |
| Promoter Holding | 80.28% | |
| Market Cap | ₹175.68 Cr. | |
